WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Pemvidutide

Governed registry record

24 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. 228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids

    DOI: 10.2337/db24-228-or

    Source identity and connection checked by Codex (AI).

  2. 228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight

    DOI: 10.2337/db25-228-or

    Source identity and connection checked by Codex (AI).

  3. 262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

    DOI: 10.2337/db24-262-or

    Source identity and connection checked by Codex (AI).

  4. 334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity

    DOI: 10.2337/db22-334-or

    Source identity and connection checked by Codex (AI).

  5. 748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide

    DOI: 10.2337/db25-748-p

    Source identity and connection checked by Codex (AI).

  6. 749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

    DOI: 10.2337/db25-749-p

    Source identity and connection checked by Codex (AI).

  7. 778-P: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model

    DOI: 10.2337/db25-778-p

    Source identity and connection checked by Codex (AI).

  8. Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators

    DOI: 10.1161/circ.146.suppl_1.13440

    Source identity and connection checked by Codex (AI).

  9. Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials

    DOI: 10.64898/2025.12.22.25342824

    Source identity and connection checked by Codex (AI).

  10. FRI-201 Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial

    DOI: 10.1016/s0168-8278(26)01936-7

    Source identity and connection checked by Codex (AI).

  11. LBP-036 Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial

    DOI: 10.1016/s0168-8278(26)00451-4

    Source identity and connection checked by Codex (AI).

  12. OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis

    DOI: 10.1016/s0168-8278(26)00326-0

    Source identity and connection checked by Codex (AI).

  13. Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial

    DOI: 10.1016/s0168-8278(22)00570-0

    Source identity and connection checked by Codex (AI).

  14. Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial

    DOI: 10.1016/s0168-8278(23)00517-2

    Source identity and connection checked by Codex (AI).

  15. SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)

    DOI: 10.1016/s0168-8278(25)01709-x

    Source identity and connection checked by Codex (AI).

  16. TOP-176 Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis

    DOI: 10.1016/s0168-8278(26)01885-4

    Source identity and connection checked by Codex (AI).

  17. WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial

    DOI: 10.1016/s0168-8278(24)01555-1

    Source identity and connection checked by Codex (AI).

  18. WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model

    DOI: 10.1016/s0168-8278(24)01560-5

    Source identity and connection checked by Codex (AI).

  19. WED-251 Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis

    DOI: 10.1016/s0168-8278(24)01588-5

    Source identity and connection checked by Codex (AI).

  20. Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.

    2026

    DOI: 10.1007/s00210-026-05257-1PMID: 41879841

  21. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.

    2025

    DOI: 10.1016/j.jhep.2024.07.006PMID: 39002641

  22. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

    2025

    DOI: 10.1016/j.jhepr.2025.101483PMID: 41113119

  23. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

    2025

    DOI: 10.1016/S0140-6736(25)02114-2PMID: 41237796

  24. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.

    2025

    DOI: 10.1016/s0140-6736(25)02304-9PMID: 41352959